论文部分内容阅读
FT_(207)是5Fu的衍生物,是目前较有效的抗癌药物之一,属嘧啶类拮拈剂,在体内干扰DNA,RNA和蛋白质的合成。为了达到通过不同途径充分发挥FT_(207)的疗效和作用,上海十二制药厂肿瘤研究室试制成FT_(207)静脉滴注冻干剂供临床应用。我院肿瘤病房于1985、8、30～1987、3、4,共应用本药治疗晚期胃癌病人18例共30疗程(以每例静滴总量20克以上为一疗程)其中可评定疗效的10例14疗程,其余8例16疗程均为手术后预防性用药。故不作评定疗效,但列入付反应观察中。一、病例与疗效:10例病人均有病理证实,其中4例未行手术治疗,4
FT_ (207) is a derivative of 5Fu and is one of the most effective anticancer drugs at present. It is a pyrimidine antagonist that interferes with DNA, RNA and protein synthesis in vivo. In order to fully realize the efficacy and role of FT_(207) in different ways, Shanghai No. 12 Pharmaceutical Factory Cancer Research Laboratory has made FT_(207) intravenous infusion of lyophilized agent for clinical application. In our hospital tumor wards in 1985,8,30-1987,3,4, a total of 18 cases of advanced gastric cancer patients were treated with this drug for 30 courses (with more than 20 grams of intravenous infusions per course as a course of treatment). 10 cases of 14 courses, the remaining 8 cases of 16 courses are postoperative prophylactic medication. Therefore, no evaluation of efficacy, but included in the observation of the reaction. I. Cases and Efficacy: 10 patients were pathologically confirmed, 4 of whom had no surgical treatment, 4